Get the Stockscreener App
1.8691
2.78%
0.0691
Serina Therapeutics Inc stock is traded at $1.8691, with a volume of 14,628.
It is up +2.78% in the last 24 hours and down -13.95% over the past month.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers.
See More
Previous Close:
$1.80
Open:
$1.85
24h Volume:
14,628
Relative Volume:
0.00
Market Cap:
$27.74M
Revenue:
$130.00K
Net Income/Loss:
$-19.22M
P/E Ratio:
-0.9865
EPS:
-1.8946
Net Cash Flow:
$-18.01M
1W Performance:
+1.09%
1M Performance:
-13.95%
6M Performance:
-55.10%
1Y Performance:
-68.10%
1-Day Range:
$1.82
$1.91
1-Week Range:
$1.7406
$1.9299
52-Week Range:
$1.22
$7.92
Serina Therapeutics Inc Stock (SER) Company Profile
Name
Serina Therapeutics Inc
Sector
Industry
Phone
(256) 327-9630
Address
601 GENOME WAY, HUNTSVILLE
Compare SER vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SER
Serina Therapeutics Inc
|
1.8618 | 26.82M | 130.00K | -19.22M | -18.01M | -1.8946 |
VRTX
Vertex Pharmaceuticals Inc
|
428.69 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.51 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.49 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
305.51 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
309.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Serina Therapeutics Inc Stock (SER) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-14-25 | Initiated | H.C. Wainwright | Buy |
Serina Therapeutics Inc Stock (SER) Latest News
Sio Capital (SER) reports 1,000,000 shares, 6.71% stake in Serina Therapeutics - Stock Titan
Serina Therapeutics (SER) Stock: Is It a Strong Investment Pick | Q4 2025: Earnings Beat EstimatesTrending Entry Points - Newser
SER Stock Price, Quote & Chart | SERINA THERAPEUTICS INC. (NYSEARCA:SER) - ChartMill
Chart Pattern Insight | Serina Therapeutics notches 33% EPS beat, tops loss estimatesPost Earnings - Newser
Serina Therapeutics (SER) stock surges over 39% after hours—here's why - MSN
Serina Therapeutics (NYSE: SER) seeks share increase and equity plan changes in 2026 proxy - Stock Titan
Serina Therapeutics Updates Executive Leadership and Governance Structure - The Globe and Mail
Serina Therapeutics Appoints New CTO, Increases CEO Salary, and Amends Bylaws in April 2026 - Minichart
Serina Therapeutics promotes Srini Tenjarla to CTO and updates company bylaws By Investing.com - Investing.com South Africa
Serina Therapeutics promotes Srini Tenjarla to CTO and updates company bylaws - Investing.com Australia
Executive pay changes and new CTO at Serina Therapeutics (NYSE: SER) - Stock Titan
Serina Therapeutics (SER) director granted 59,667 dividend shares - Stock Titan
Director at Serina Therapeutics (SER) receives 7,553 share grant - Stock Titan
Serina names Srini Tenjarla CTO; raises CEO Steve Ledger's salary - TradingView
Serina Therapeutics, Inc. (SER) - Minichart
Share increase to 125M, 2M-plan reserve sought by Serina (NYSE: SER) - Stock Titan
Market Review: What is the dividend yield of Serina Therapeutics IncWeekly Trend Recap & Verified Momentum Stock Alerts - baoquankhu1.vn
Take Profit: What is the dividend yield of Serina Therapeutics IncMarket Growth Report & Free High Return Stock Watch Alerts - baoquankhu1.vn
Serina Therapeutics to Present at the 5th LNP Formulation & Process Development Summit - Sahm
Serina Therapeutics, Inc Announces Novel Lipid Nanoparticles Built On POZ Platform - marketscreener.com
Recap Report: Will PHUN be affected by tariffs2026 PreEarnings & Risk Controlled Swing Alerts - baoquankhu1.vn
Serina says its nanoparticle polymer avoided antibodies in rat study - Stock Titan
Serina Therapeutics Announces NYSE American Acceptance of Continued Listing Compliance Plan - Sahm
Serina Therapeutics wins NYSE approval; 2027 listing compliance deadline set - MSN
Serina Therapeutics announces NYSE American acceptance of continued listing compliance plan - marketscreener.com
Serina Therapeutics Announces NYSE American Acceptance Of Continued Listing Compliance Plan - TradingView
SER Technical Analysis & Stock Price Forecast - Intellectia AI
Stock List: Research Stocks from Around the World - GuruFocus
Serina Therapeutics (SER) files 10-K amendment to correct auditor consent - stocktitan.net
New funding to support Serina’s SER-252 trial in advanced Parkinson’s - Parkinson's News Today
SER Stock Price and Chart — AMEX:SER - TradingView
Serina Therapeutics POZ Drug Delivery Platform: Technology Overview, Pipeline, and Intellectual Property Portfolio - Minichart
Serina Therapeutics' 2025 net loss widens as R&D expenses jump - TradingView
Serina Therapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights - marketscreener.com
Serina Therapeutics (NYSE: SER) posts 2025 loss while funding SER-252 trials - Stock Titan
[10-K] Serina Therapeutics, Inc. Fi... - Stock Titan
Serina Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
Top Executive Makes Notable Move With Serina Therapeutics Stock - TipRanks
Serina Therapeutics CSO Moreadith sells $18,567 in stock - Investing.com
Serina Therapeutics CSO Moreadith sells $18,567 in stock By Investing.com - Investing.com Canada
Serina Therapeutics (SER) CSO exercises options then sells 6,500 shares - Stock Titan
Serina Therapeutics Raises Up to $30 Million to Advance SER-252 Parkinson’s Drug Trial and Secures Additional Funding Opportunities - Minichart
Serina Therapeutics to Present at 38th Annual Roth Conference - National Today
Serina Therapeutics to Present at the 38th Annual Roth Conference - Bitget
Serina Therapeutics Inc appoints Greg Bailey as co-chairman of boardSEC filing - MarketScreener
Serina Therapeutics IncAppoints Greg Bailey As Co-Chairman Of BoardSEC Filing - TradingView — Track All Markets
Serina Therapeutics (SER) lines up $30M private placement plus $33.3M warrant upside - Stock Titan
Serina Therapeutics Inc. Faces Stock Volatility Amid Economic Challenges - StocksToTrade
Serina Therapeutics Inc Stock (SER) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.78%
3.01%
Cap:
|
Volume (24h):